Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
COGT
Stock Latest News
Ratings
Cogent Biosciences Earns Buy Rating as Bezuclasnib Advances Toward 2027 PDUFA and Multiple 2026 Catalysts; $55 Price Target Reaffirmed
3d ago
COGT
Premium
The Fly
Cogent Biosciences reports FDA acceptance of bezuclastinib new drug application
3d ago
COGT
Premium
The Fly
Cogent Biosciences added to Analyst Focus List at JPMorgan
9d ago
COGT
Premium
Company Announcements
Cogent Biosciences Secures Long-Term Bezuclastinib Supply Deal
15d ago
8K
COGT
Premium
Ratings
Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position
30d ago
COGT
Premium
The Fly
Cogent’s Q2 results broadly in line with expectations, says H.C. Wainwright
30d ago
COGT
Premium
The Fly
Cogent Biosciences price target raised to $55 from $52 at Piper Sandler
1M ago
COGT
Premium
The Fly
Cogent Biosciences price target raised to $52 from $45 at Guggenheim
1M ago
COGT
Premium
Company Announcements
Cogent Biosciences Announces $400 Million ATM Offering
1M ago
8K
COGT
Premium
Ratings
Regulatory Catalysts and Launch Readiness for Bezuclasitinib Underpin Sam Slutsky’s Buy Rating on Cogent Biosciences
1M ago
COGT
Premium
Pre-Earnings
COGT Earnings this Week: How Will it Perform?
1M ago
COGT
Premium
The Fly
Cogent Biosciences submits bezuclastinib NDA to FDA
3M ago
COGT
Premium
Company Announcements
Cogent Biosciences Shareholders Back Board, Governance Proposals
3M ago
8K
COGT
Premium
The Fly
Cogent Biosciences announces data from analysis of PEAK Phase 3 trial
4M ago
COGT
Premium
The Fly
Cogent Biosciences announces FDA acceptance of bezuclastinib NDA
4M ago
COGT
Premium
The Fly
Cogent Biosciences price target raised to $55 from $52 at H.C. Wainwright
4M ago
COGT
Premium
The Fly
Cogent Biosciences announces preclinical data from KRAS, ErbB2 programs
5M ago
COGT
Premium
Ratings
Bezuclastinib’s Strong Phase 3 GIST Data and NDA Catalyst Support Buy Rating and $52 Target
6M ago
COGT
Premium
The Fly
Cogent Biosciences submits bezuclastinib new drug application to the FDA
6M ago
COGT
Premium
Company Announcements
Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers
6M ago
COGT
Premium
The Fly
Cogent Biosciences assumed with a Buy at Jefferies
6M ago
COGT
Premium
The Fly
Cogent Biosciences: FDA accepts NDA for bzuclastinib in NonAdvSM
6M ago
COGT
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
